Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia.
The approval for the pilocarpine HCl ophthalmic solution 1.25% was granted Oct. 28, according to the FDA’s website.
In this exclusive video, George O. Waring IV, MD, principal investigator for the GEMINI I and GEMINI 2 phase 3 clinical studies of Vuity for the treatment of presbyopia, discusses the importance of the approval to the ophthalmic community.
“We learned that this drug has a rapid onset of almost 15 minutes and an (Read more...)